Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Metabolism of Omega-3 and Omega-6 During Healthy Aging

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02957188
Recruitment Status : Completed
First Posted : November 7, 2016
Last Update Posted : November 7, 2016
Sponsor:
Collaborator:
Healthy Aging Research Network
Information provided by (Responsible Party):
Mélanie Plourde, Université de Sherbrooke

Brief Summary:
The purpose of this study is to determine the kinetics of 13C-eicosapentaenoic acid (EPA) and 13C-arachidonic acid (AA) in young and older participants

Condition or disease Intervention/treatment
Healthy Volunteers Other: 13C eicosapentaenoic acid and 13C arachidonic acid

Layout table for study information
Study Type : Observational
Actual Enrollment : 13 participants
Observational Model: Case-Crossover
Time Perspective: Cross-Sectional
Official Title: Metabolism of Uniformly Labelled 13C Eicosapentaenoic Acid and 13C Arachidonic Acid During Healthy Aging
Study Start Date : August 2015
Actual Primary Completion Date : July 2016
Actual Study Completion Date : August 2016

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Young
Six young (18-30 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
Other: 13C eicosapentaenoic acid and 13C arachidonic acid
Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.

Elderly
Six older (≥ 70 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
Other: 13C eicosapentaenoic acid and 13C arachidonic acid
Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.




Primary Outcome Measures :
  1. Kinetics of 13C-EPA and 13C-AA [ Time Frame: Plasma incorporation of 13C-EPA or 13C-AA was measured from the area under the curve in young and older participants over 28 days post-dose ]

Biospecimen Retention:   Samples With DNA
Fasted blood samples were collected before breakfast (baseline) and thereafter at 2 h, 4 h, 6 h, 24 h, 7 d, 14 d, after the tracer intake.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Young and elderly healthy participants
Criteria

Inclusion Criteria:

  • six young (18-30 y old) and six older (≥ 70 y old)
  • healthy non medicated participants.

Exclusion Criteria:

  • Tobacco,
  • malnutrition (assessed from blood albumin, haemoglobin and lipids), -
  • participants taking an EPA+DHA supplements or consuming more than 2 fish meals per week,
  • severe gastro-intestinal problems,
  • medication for diabetes,
  • thyroid disease,
  • renal failure,
  • cancer,
  • psychiatric difficulties or depression,
  • cardiovascular disease,
  • glucose intolerance (>8 mmol/L in fasted samples)
  • chronic immune condition or inflammation (CRP > 10 mg/l, white cell count),
  • recent major surgery or cardiac event,
  • dementia,
  • ongoing or past severe drug or alcohol abuse,
  • ongoing or past intensive physical training.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Mélanie Plourde, Professor, Université de Sherbrooke
ClinicalTrials.gov Identifier: NCT02957188     History of Changes
Other Study ID Numbers: 13C EPA and 13C AA metabolism
First Posted: November 7, 2016    Key Record Dates
Last Update Posted: November 7, 2016
Last Verified: November 2016

Keywords provided by Mélanie Plourde, Université de Sherbrooke:
Eicosapentaenoic acid
Arachidonic acid
Metabolism
Healthy aging